Increased levels of urinary PGE-M, a biomarker of inflammation, occur in association with obesity, aging, and lung metastases in patients with breast cancer.
about
Network Marker Selection for Untargeted LC-MS Metabolomics Data.Urinary PGE-M levels are associated with risk of colorectal adenomas and chemopreventive response to anti-inflammatory drugs.Role of inflammation and inflammatory mediators in colorectal cancerInactivating mutation in the prostaglandin transporter gene, SLCO2A1, associated with familial digital clubbing, colon neoplasia, and NSAID resistance.Use of nonsteroidal anti-inflammatory drugs and reduced breast cancer risk among overweight women.Urinary PGE-M in colorectal cancer: predicting more than risk?Targeted lipidomic strategies for oxygenated metabolites of polyunsaturated fatty acids.Urinary prostaglandin E2 metabolite and pancreatic cancer risk: case-control study in urban ShanghaiMenopause is a determinant of breast adipose inflammationWeight change in breast cancer survivors compared to cancer-free women: a prospective study in women at familial risk of breast cancer.PPARδ and PGE2 signaling pathways communicate and connect inflammation to colorectal cancerProstaglandin E2 activates the mTORC1 pathway through an EP4/cAMP/PKA- and EP1/Ca2+-mediated mechanism in the human pancreatic carcinoma cell line PANC-1Phase Ib Randomized, Double-Blinded, Placebo-Controlled, Dose Escalation Study of Polyphenon E in Patients with Barrett's Esophagus.Prostaglandin E2 Promotes Colorectal Cancer Stem Cell Expansion and Metastasis in Mice.Factors Associated with Multiple Biomarkers of Systemic Inflammation.An inflammatory mediator, prostaglandin E2, in colorectal cancer.Obesity and Cancer: Concepts and ChallengesAssociation between urinary prostaglandin E2 metabolite and breast cancer risk: a prospective, case-cohort study of postmenopausal women.Dietary polyphenols suppress elevated levels of proinflammatory mediators and aromatase in the mammary gland of obese mice.Urinary PGE-M: a promising cancer biomarkerMolecular pathways: adipose inflammation as a mediator of obesity-associated cancer.ASPirin Intervention for the REDuction of colorectal cancer risk (ASPIRED): a study protocol for a randomized controlled trial.Impact of obesity on the survival of patients with early-stage squamous cell carcinoma of the oral tongue.The obesity-inflammation-eicosanoid axis in breast cancer.Obesity-associated cancer risk: the role of intestinal microbiota in the etiology of the host proinflammatory state.Obesity and Cancer Mechanisms: Tumor Microenvironment and Inflammation.A Prospective Study of Urinary Prostaglandin E2 Metabolite, Helicobacter pylori Antibodies, and Gastric Cancer Risk.Urinary levels of prostaglandin E2 are positively correlated with intratumoral infiltration of Foxp3+ regulatory T cells in non-small cell lung cancer.COX2 induction: a mechanism of endocrine breast cancer resistance?Postmenopausal breast cancer and oestrogen associations with the IgA-coated and IgA-noncoated faecal microbiota.Obesity and Cancer: Existing and New Hypotheses for a Causal Connection.JAK2 and AMP-kinase inhibition in vitro by food extracts, fractions and purified phytochemicals.
P2860
Q31160080-120C5681-AE9D-43C9-8D57-6E935AE09469Q33857191-9F0BC8C7-E41C-4BB8-8663-B90D2E8D1A43Q33957824-738BAFF1-AA90-4657-939F-1F8079A8D586Q34017114-472ECF3D-5DF1-4E44-B650-E0A4F57E20E1Q34034263-D71EE5AF-0371-4228-B63E-3CCFF7FA7E88Q34289285-78D6E332-C31E-4FAD-9314-2A8850C204A3Q35070934-7E5DF9F1-B050-4002-BDA1-2809C4B24E54Q35094999-094790E4-E9BE-4AC3-8FE9-58BBEA617719Q35563031-822BC9F8-001A-4364-8346-E14B8BF6F66FQ35935790-7D3DD5E3-AD7E-4C9D-A266-C57111A84047Q35963300-8A88FDC8-FBB2-493F-BA9B-F9F133922E99Q36297552-B91FC60D-1D9C-494E-ABBA-B80E9A12BAA7Q36349535-0309FAE2-99BF-43C1-B413-AE64E1420AEBQ36604053-65A34B16-6DB4-4E98-B911-13FD0CB3C145Q36655802-4370CF54-386F-4F7F-8E97-30A824D9982CQ36701908-AEE1E232-F141-448E-90BE-556BE0E12F39Q36734737-B254E73B-F4E4-4652-A5A5-2B61203D6E2BQ36916609-3E016B11-829F-4C8B-AAE7-F63B41CAA462Q37157059-2CF7C754-440F-41C5-9F2F-498C648F9523Q37166867-D971C615-75D6-4BA6-9B26-72A402522D1DQ37478905-EEEAE76C-3780-4B43-B48C-693D87311E75Q37618698-8BD9BBFD-9C16-46E9-8408-BC0E5DC4EC97Q37652901-E9DE64E5-757A-44D9-A365-44C8502F163AQ38156366-7A21CEA5-F57D-48CA-8C0B-DC7D1E4DEFC8Q38927355-BB8CDDF7-0B52-4E87-92A3-28FEB1B96DC5Q39024774-9E45190B-4E1A-43BC-BBD4-D458B1F34276Q40246172-CB0F3ED8-D927-4F6B-950C-82B33306EE53Q41142487-536DBF2A-04F4-4E07-879A-E0E73144EFA2Q47722410-EF917644-090D-4A93-BC35-18C7220B9A4AQ50155271-C4B24B1F-2405-4AD1-8A46-6FB7F22B827DQ52662023-A0149F10-2145-46A2-98B3-42542E14A019Q55069618-2F31FEED-2EDE-48B7-9D92-CB1AB2461602
P2860
Increased levels of urinary PGE-M, a biomarker of inflammation, occur in association with obesity, aging, and lung metastases in patients with breast cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 26 March 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Increased levels of urinary PG ...... n patients with breast cancer.
@en
Increased levels of urinary PG ...... n patients with breast cancer.
@nl
type
label
Increased levels of urinary PG ...... n patients with breast cancer.
@en
Increased levels of urinary PG ...... n patients with breast cancer.
@nl
prefLabel
Increased levels of urinary PG ...... n patients with breast cancer.
@en
Increased levels of urinary PG ...... n patients with breast cancer.
@nl
P2093
P2860
P921
P1476
Increased levels of urinary PG ...... n patients with breast cancer.
@en
P2093
Andrew J Dannenberg
Chau T Dang
Clifford A Hudis
Daniel Goldstein
Laura C Hawks
Monica N Fornier
Patrick G Morris
Xi Kathy Zhou
P2860
P304
P356
10.1158/1940-6207.CAPR-12-0431
P577
2013-03-26T00:00:00Z